busulfan and thiotepa
busulfan has been researched along with thiotepa in 194 studies
Research
Studies (194)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (19.07) | 18.7374 |
| 1990's | 29 (14.95) | 18.2507 |
| 2000's | 34 (17.53) | 29.6817 |
| 2010's | 56 (28.87) | 24.3611 |
| 2020's | 38 (19.59) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eriksson, G; Lambert, B | 1 |
| Stukov, AN | 1 |
| Brugieres, L; Couanet, D; Demeocq, F; Hartmann, O; Kalifa, C; Lemerle, J; Terrier-Lacombe, MJ; Valteau, D; Vassal, G | 1 |
| Bell, J; Clarke, EA; Day, NE; Høst, H; Kaldor, JM; Karjalainen, S; Mehnert, W; Pedersen, D; Pettersson, F; Prior, P | 1 |
| Faktorowich, Y; Lapidot, T; Lubin, I; Martelli, MF; Rabi, I; Reisner, Y; Salomon, O; Terenzi, A | 1 |
| Ehrsson, H; Eksborg, S | 1 |
| Renner, HW | 1 |
| Gori, GB; Kniazeff, AJ; Shimkin, MB; Stoner, GD; Weisburger, EK; Weisburger, JH | 1 |
| Fickers, M; Speck, B | 1 |
| Hoshi, A; Kanzawa, F; Kuretani, K | 1 |
| Greenwald, ES | 1 |
| Hartwich, G | 1 |
| Lepeshkina, GN; Rossolimo, OK | 2 |
| Calcutt, G | 1 |
| Karzel, K; Schmid, I | 1 |
| Hoshi, A; Kanzawa, F; Kumagai, K; Kuretani, K | 1 |
| Berman, I; Dauer, MM; McCabe, B | 1 |
| Carlisle, HN; Saslaw, S | 1 |
| Shapovalova, SP | 1 |
| Karsten, C; Krüger, C; Scherf, HR | 1 |
| Tsunoda, Y | 1 |
| Peychl, L; Vortel, V | 1 |
| Schmähl, D | 1 |
| Schmidt, CG | 1 |
| Doskocz, W; Giełdanowski, J | 1 |
| Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B | 1 |
| Andersson, BS; Bellare, N; Gajewski, JL; Giralt, SA; Khouri, IF; McCarthy, P; Mehra, R; Nath, R; Przepiorka, D; van Besien, KW | 1 |
| Appelbaum, FR; Bensinger, WI; Brunvand, M; Gooley, T; Lilleby, K; Petersdorf, S; Rivkin, S; Rowley, S; Sandmaier, B; Weaver, CH | 1 |
| Andersson, B; Cork, A; Deisseroth, AB; Giralt, S; Ippoliti, C; Lee, M; Luna, M; Mehra, R; Przepiorka, D; van Beisen, K | 1 |
| Champlin, RE; Diener, K; Dimopoulos, M; Ippoliti, C; Luna, M; Przepiorka, D; Smith, T | 1 |
| Alexanian, R; Andersson, B; Delasalle, KB; Dimopoulos, MA; Giralt, S; Hester, J; Mehra, R; Przepiorka, D; Reading, C; van Besien, K | 1 |
| Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB | 1 |
| Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Gooley, T; Holmberg, L; Klarnet, JP; Lilleby, K; Maziarz, R; Montgomery, P; Petersdorf, S; Rivkin, S; Rowley, S; Sanders, JE; Schiffman, KS; Storb, R; Trueblood, K; Weaver, CH; Weiden, P; Zuckerman, N | 1 |
| Couanet, D; Doz, F; Grill, J; Hartmann, O; Kalifa, C; Sainte-Rose, C; Schoepfer, C; Terrier-Lacombe, MJ; Valteau-Couanet, D | 1 |
| Benhamou, E; Bouffet, E; Coze, C; Doz, F; Dupuis-Girod, S; Hartmann, O; Kalifa, C; Mechinaud, F | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Ellis, E; Hertler, A; Holmberg, L; Klarnet, JP; Lilleby, K; Maziarz, R; McCroskey, R; Montgomery, P; Nichols, W; Petersdorf, S; Rivkin, S; Rowley, S; Schiffman, KS; Weaver, CH; Weiden, P | 1 |
| Amin, K; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, R; Gajewski, J; Giralt, S; Hester, J; Khouri, I; Korbling, M; Mehra, R; Mirza, N; Przepiorka, D; Pugh, WC; Seong, D; Thall, P; van Besien, K | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Clift, R; Gooley, T; Holmberg, L; Klarnet, J; Lilleby, K; Maloney, DG; Maziarz, R; Press, O; Schiffman, K; Weaver, C; Zuckerman, N | 1 |
| Fujisaki, H; Fukuzawa, M; Hara, J; Matsuda, Y; Nakanishi, K; Ohta, H; Okada, A; Okada, S; Osugi, Y; Takai, K; Tokimasa, S | 1 |
| Finlander, R; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Demirer, T; Gersh, R; Goldberg, R; Goodman, G; Harrer, G; Holmberg, LA; Jacobs, A; Klarnet, J; Maziarz, R; McCloskey, R; Montgomery, P; Nichols, W; Rivkin, S; Rowley, S; Weiden, P; Zuckerman, N | 1 |
| Grill, J; Kalifa, C | 1 |
| Cividalli, G; Nagler, A; Naparstek, E; Or, R; Peylan-Ramu, N; Rosales, F; Slavin, S; Varadi, G | 1 |
| Andersson, B; Champlin, R; Deisseroth, AB; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, I; Körbling, M; Lee, MS; Mehra, R; Przepiorka, D; Thall, P; van Besien, K | 1 |
| Ishii, T; Satoh, T; Tatezaki, S; Yonemoto, T | 1 |
| Bilgrami, S; Chakraborty, N; Guo, C; Maness, L; Mukherji, B; Perez-Diez, A; Tutschka, P | 1 |
| Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A | 1 |
| Bensinger, W; Gooley, T; Lee, JL; McDonald, GB; Schiffman, K | 1 |
| Chan, K; Culbert, S; Mullen, C; Petropoulos, D; Przepiorka, D; Roberts, W; Tran, H; Worth, L | 1 |
| Nagler, A; Naparstek, E; Or, R; Rosales, F; Slavin, S; Varadi, G | 1 |
| Bouffet, E; Chastagner, P; Demeocq, F; Doz, F; Gentet, JC; Hartmann, O; Kalifa, C; Lutz, P; Raquin, M; Rodary, C | 1 |
| Barnett, T; Bensinger, W; Gooley, T; Hawkins, D; Sanders, J | 1 |
| Appelbaum, FR; Bensinger, W; Gutierrez-Delgado, F; Holmberg, LA; Hooper, H; Kawahara, K; Livingston, RB; Maziarz, RT; Montgomery, P; Rivkin, S; Weiden, P | 1 |
| Bensinger, WI; Chauncey, TR; Gooley, TA; Holmberg, L; Lilleby, K; Lloid, ME; Schubert, MM | 1 |
| Bondiau, PY; Foa, C; Magné, N; Otto, J; Thyss, A | 1 |
| Achour, E; Azar, N; Belanger, C; Cassoux, N; Delattre, JY; Gerber, S; Hoang-Xuan, K; Leblond, V; Levy, V; Ribrag, V; Soussain, C; Suzan, F | 1 |
| Ayala, F; Cano, H; Martínez, F; Moraleda, J; Perez-Ceballos, E; Vallejo, C; Vicente, V | 1 |
| Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
| Inagawa, H; Kami, M; Kawagoe, S; Kishi, Y; Machida, U; Matsumura, T; Matsushita, H; Miyakoshi, S; Miyazaki, M; Mori, M; Morinaga, S; Muto, Y; Ueyama, J | 1 |
| Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K | 1 |
| Aleman, A; Alexanian, R; Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Dimopoulos, M; Donato, M; Giralt, S; Khouri, I; Korbling, M; Shimoni, A; Smith, TL; Ueno, NT; Weber, D | 1 |
| Adachi, S; Akiyama, Y; Kubota, M; Lin, YW; Nakahata, T; Umeda, K; Usami, I; Watanabe, K | 1 |
| McCune, JS; Slattery, JT | 1 |
| Chaudhry, A; Cheng, T; Forsyth, P; Glück, S; Morris, D; Russell, JA; Stewart, DA | 1 |
| Appelbaum, F; Bensinger, W; Chauncey, T; Gutierrez-Delgado, F; Holmberg, L; Hooper, H; Maloney, D; Maziarz, R; Petersdorf, S; Press, O | 1 |
| AMBRUS, JL; BACK, N | 1 |
| BIERMAN, HR | 1 |
| SCHUBERTH, J; SORBO, B | 1 |
| BOHUON, B; BOHUON, C; DELACOUX, E; TRUHAUT, R | 1 |
| KIMURA, K; KURITA, S | 1 |
| STANISLAVSKAIA, MS | 1 |
| MATSUOKA, M | 1 |
| GOLDENBERG, DM | 1 |
| NANETTI, L; VALLINI, R | 1 |
| DALMAIS, J; GUINGAND, M; PLAUCHU, M | 1 |
| LOPESCARDOZO, E | 1 |
| BLUMBERG, NA; CHORIN, VA; GOLDBERG, LE; ROSSOLIMO, OK; STANISLAVSKAYA, MS; VERTOGRADOVA, TP | 1 |
| ORBACH-ARBOUYS, S | 1 |
| HARMAN, JB | 1 |
| Boland, I; Bouligand, J; Deroussent, A; Hartmann, O; Kalifa, C; Valteau-Couanet, D; Vassal, G | 1 |
| Hoang-Xuan, K; Levy, V; Soussain, C | 1 |
| Aleman, A; Alexanian, R; Anagnostopoulos, A; Ayers, G; Champlin, R; Donato, M; Giralt, S; Weber, D | 1 |
| Díaz, MA; González-Vicent, M; Lassaletta, A; Madero, L; Pérez-Martínez, A; Sevilla, J | 1 |
| Benhamou, E; Couanet, D; Fillipini, B; Grill, J; Habrand, JL; Hartmann, O; Kalifa, C; Valteau-Couanet, D | 1 |
| Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH | 1 |
| Benhamou, E; Bouligand, J; Drouard-Troalen, L; Grill, J; Hartmann, O; Le Maitre, A; Paci, A; Valteau-Couanet, D; Vassal, G | 1 |
| Doz, F; Frappaz, D; Gentet, JC; Grill, J; Habrand, JL; Kalifa, C; Raquin, MA; Ridola, V; Sainte-Rose, C; Valteau-Couanet, D | 1 |
| Abdul-Hai, A; Ergas, D; Resnick, IB; Shapira, MY; Slavin, S; Weiss, L | 1 |
| Aleman, A; Anderson, KO; Brown, J; Campagnaro, E; Cleeland, C; Giralt, S; Mendoza, F; Roden, L; Saliba, R; Weber, D | 1 |
| Casasnovas, O; Choquet, S; Dupriez, B; Fourme, E; Gisselbrecht, C; Hoang-Xuan, K; Jaccard, A; Janvier, M; Kolb, B; Leblond, V; Omuro, A; Sanson, M; Souleau, B; Soussain, C; Taillandier, L; Taksin, AL; Witz, F; Zini, JM | 1 |
| Abrey, LE; Cairncross, JG; Forsyth, P; Kewalramani, T; Louis, DN; Mohile, NA; Paleologos, N; Raizer, JJ; Stewart, D | 1 |
| Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N | 1 |
| Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
| Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M | 1 |
| Kim, SJ; Kim, WS; Lee, DH; Lee, SC; Suh, C; Won, JH | 1 |
| Anson, J; Gollard, RP; Khoury, J; Mason, J; Rosen, L | 1 |
| Abhyankar, S; Aljitawi, O; Divine, C; Ganguly, S; Jain, V; McGuirk, J | 1 |
| Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C | 1 |
| Abramson, JS; Armand, P; Batchelor, TT; Chen, YB; Cote, GM; Drappatz, J; Fisher, DC; Hochberg, EP; Hochberg, FH; LaCasce, AS; McAfee, SL; Muzikansky, A | 1 |
| Alimohamed, N; Daly, A; Duggan, P; Owen, C; Stewart, DA | 1 |
| Hirai, M; Iwai, F; Kaneko, H; Matsui, Y; Miura, Y; Toyooka, N; Tsudo, M; Watanabe, M | 1 |
| Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C | 1 |
| Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J | 1 |
| Angelopoulou, MK; Beris, P; Constantinou, N; Dervenoulas, J; Diamantopoulos, P; Dimopoulos, MA; Dimou, M; Economopoulou, C; Economopoulou, P; Efthimiou, A; Georgiou, G; Kalpadakis, C; Katsigiannis, A; Korkolopoulou, P; Kotsianidis, I; Kyrtsonis, MC; Levidou, G; Meletis, J; Panayiotidis, P; Pangalis, GA; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vassilakopoulos, TP | 1 |
| Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M | 1 |
| Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R | 1 |
| Blanchard, P; Couanet, D; Dhermain, F; Dufour, C; Goma, G; Grill, J; Habrand, JL; Kieffer, V; Negretti, L; Valteau-Couanet, D | 1 |
| Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK | 1 |
| Boldrini, R; Castellano, A; Contoli, B; Corneli, T; Crocoli, A; DE Ioris, MA; DE Pasquale, MD; DE Sio, L; Garganese, MC; Jenkner, A; Pessolano, R; Serra, A | 1 |
| Bartels, U; Bouffet, E; Huang, A; Mosleh, O; Schechter, T; Tabori, U | 1 |
| Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM | 1 |
| Bains, T; Chen, AI; Dibb, W; Hayes-Lattin, BM; Leis, JF; Lemieux, A; Maziarz, RT | 1 |
| Bergthold, G; Dhermain, F; Dufour, C; El Kababri, M; Goma, G; Grill, J; Kieffer, V; Raquin, MA; Sainte-Rose, C; Valteau-Couanet, D; Varlet, P | 1 |
| Faivre, G; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Weaver, SA; Welch, MR | 1 |
| Berritta, D; Cupri, A; Fauci, AL; Leotta, S; Milone, G; Parisi, M; Spina, P; Tripepi, G | 1 |
| Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C | 1 |
| Armand, P; Ballen, KK; Barnes, J; Batchelor, T; Brezina, M; Chen, YB; Chi, AS; Curtis, M; Del Rio, C; Dietrich, J; Driscoll, J; Gertsner, ER; Hochberg, E; Hochberg, F; Jones, S; LaCasce, AS; Li, S; McAfee, SL; Nayak, L; Spitzer, TR | 1 |
| Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I | 1 |
| Abrey, LE; Baser, RE; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, CC; Kaley, TJ; Matasar, MJ; Moskowitz, CH; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Sauter, CS | 1 |
| Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C | 1 |
| Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L | 1 |
| Chua, N; Oh, DH; Stewart, DA; Street, L | 1 |
| Champagne, C; Farrant, P; Taylor, M | 1 |
| Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ | 1 |
| Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI | 1 |
| Kang, ES; Kim, HS; Kim, SJ; Kim, WS; Ko, YH; Lee, JY; Lee, MY; Lim, SH | 1 |
| Dufour, C; Goma, G; Lapierre, V; Pasqualini, C; Raquin, MA; Valteau-Couanet, D | 1 |
| Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H | 1 |
| Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M | 1 |
| Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S | 1 |
| Evans, AT; Gooley, TA; McCune, JS; McDonald, GB; Ostrow, JD; Schoch, G | 1 |
| Armand, P; Batchelor, TT; Chen, YB; DeFilipp, Z; El-Jawahri, A; Li, S; Nayak, L; Wang, N | 1 |
| Kotecha, RS; Miles, GCP; Rajagopal, R | 1 |
| Armand, P; Batchelor, TT; Brunner, AM; Chen, YB; Collier, K; DeFilipp, Z; Hochberg, E; Li, S; Qualls, D; Sullivan, A | 1 |
| Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
| Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y | 1 |
| Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, SS; Yoon, JH | 1 |
| Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J | 1 |
| Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D | 1 |
| Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A | 1 |
| Chua, N; Larouche, JF; Owen, C; Sanders, S; Shafey, M; Stewart, DA | 1 |
| Hong, JY; Huh, J; Hyung, J; Kim, JH; Kim, S; Lee, SW; Park, CS; Park, JS; Ryu, JS; Suh, C; Yoon, DH | 1 |
| Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J | 1 |
| Frączkiewicz, J; Gajek, K; Kałwak, K; Mielcarek-Siedziuk, M; Raciborska, A; Rosa, M; Rybka, B; Ryczan-Krawczyk, R; Salamonowicz, M; Ślęzak, A; Ussowicz, M; Wawrzyniak-Dzierżek, E; Węcławek-Tompol, J | 1 |
| Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ | 1 |
| Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R | 1 |
| Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I | 1 |
| Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J | 1 |
| Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E | 1 |
| Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B | 1 |
| Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B | 1 |
| Akisue, T; Hara, H; Hayakawa, A; Iijima, K; Ishiko, S; Kawamoto, T; Mori, T; Nino, N; Nishimura, N; Takafuji, S; Uemura, S; Yamamoto, N | 1 |
| Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA | 1 |
| Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L | 1 |
| Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G | 1 |
| Aiba, A; Hishizawa, M; Kitano, T; Kondo, T; Nishikori, M; Shimazu, Y; Shindo, T; Takaori-Kondo, A; Wada, F; Watanabe, M | 1 |
| Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A | 1 |
| Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I | 1 |
| Angelucci, E; Bacigalupo, A; Barosi, G; Bregante, S; Casarino, L; Chiusolo, P; De Stefano, V; Di Grazia, C; Dominietto, A; Giammarco, S; Gualandi, F; Guolo, F; Lamparelli, T; Laurenti, L; Metafuni, E; Raiola, AM; Rossi, E; Rossi, M; Sica, S; Signori, A; Sora, F; Vannucchi, A | 1 |
| Kapoor, R; Rastogi, N; Yadav, SP | 1 |
| Angelucci, E; Autore, F; Bacigalupo, A; Bregante, S; Chiusolo, P; Di Grazia, C; Giammarco, S; Gualandi, F; Innocenti, I; Laurenti, L; Metafuni, E; Murgia, B; Raiola, AM; Sica, S; Sora, F; Varaldo, R | 1 |
| Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A | 1 |
| Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A | 1 |
| Hill, JM; Meehan, KR | 1 |
| Abe, M; Fujii, S; Harada, T; Hori, T; Kagawa, K; Kawata, S; Miki, H; Murai, J; Nakamura, S; Oura, M; Sogabe, K; Sumitani, R; Takahashi, M | 1 |
| Aquino, VM; Baker, KS; Chellapandian, D; Dávila Saldaña, B; Duncan, CN; Dvorak, CC; Eapen, M; Eckrich, MJ; Gennery, AR; Georges, GE; Hebert, K; Kim, S; Lugt, MV; Marsh, RA; Olson, TS; Pulsipher, MA; Shenoy, S; Stenger, E; Yu, LC | 1 |
| Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A | 1 |
| Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D | 1 |
| Abraham, J; Agbetiafa, K; Ahle, G; Bonmati, C; Bouabdallah, K; Bouabdallah, R; Bourget, P; Casasnovas, O; Charron, C; Chauchet, A; Chinot, O; Choquet, S; Cornillon, J; Damaj, G; Delwail, V; Dorvaux, V; Fabbro, M; Fornecker, LM; Ghesquières, H; Giordan, Q; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Houot, R; Jabeur, W; Jardin, F; Le Garff-Tavernier, M; Malaise, D; Marolleau, JP; Moluçon-Chabrot, C; Morschhauser, F; Nichelli, L; Oberic, L; Peyrade, F; Plessier, A; Roland, V; Schenone, L; Schmitt, A; Soussain, C; Taillandier, L; Tanguy, ML; Tempescul, A; Thieblemont, C; Touitou, V; Ursu, R; Wantz-Mézières, S; Waultier-Rascalou, A; Willems, L | 1 |
| Chua, N; Puckrin, R; Shafey, M; Stewart, DA | 1 |
| Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Halder, R; Kapoor, J; Mehta, P; Singh, A; Singh, R; Verma, M; Yadav, N | 1 |
| Baehring, JM; Kaulen, LD | 1 |
| Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z | 1 |
| Hazuku, T; Kawano, K; Kodama, Y; Maruyama, R; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Urabe, S; Wada, J | 1 |
| Chen, J; Ding, Y; Hou, Y; Huang, X; Huang, Y; Li, X; Luo, C; Song, Q; Wu, G; Xu, S | 1 |
| Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I | 1 |
| Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S | 1 |
| Bérengère, G; Bruno, R; Delphine, L; Jean-Pierre, M; Magalie, J; Patrick, V; Pierre, M; Pierre-Edouard, D | 1 |
| Cascio, E; Castillo, P; Farhadfar, N; Fort, J; Fraser, A; Horn, B; Lamba, J; Moore-Higgs, G; Slayton, W | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
Reviews
11 review(s) available for busulfan and thiotepa
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug level monitoring: cytostatics.
Topics: Alkylating Agents; Aminoacridines; Amsacrine; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bleomycin; Busulfan; Chlorambucil; Chromatography, Gas; Chromatography, Liquid; Cisplatin; Cyclophosphamide; Cytarabine; Fluorouracil; Humans; Mass Spectrometry; Melphalan; Methotrexate; Mitomycins; Monitoring, Physiologic; Nitrosourea Compounds; Podophyllotoxin; Purines; Thiotepa; Vinca Alkaloids | 1985 |
Cancer chemotherapy. I.
Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Female; Humans; Male; Mechlorethamine; Melphalan; Methotrexate; Mice; Neoplasms; Thiotepa | 1972 |
[Side-effects of cytostatic therapy with special reference to potential carcinogenic effects].
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Busulfan; Fluorouracil; Hemangiosarcoma; Mercaptopurine; Mitomycins; Neoplasms; Neoplasms, Experimental; Podophyllin; Rats; Sarcoma, Experimental; Thiotepa; Vinblastine | 1971 |
[Alkylating cytostatic agents].
Topics: Alkylating Agents; Alkylation; Animals; Busulfan; Cell Division; Chemical Phenomena; Chemistry; Chlorambucil; Cyclophosphamide; DNA Viruses; Ethers, Cyclic; Ethoglucid; Ethylamines; Humans; Mannomustine; Melphalan; Neoplasms; Nitrogen Mustard Compounds; Thiotepa; Triaziquone | 1971 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa | 1995 |
[High-dose chemotherapy in relapse of medulloblastoma in young children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cerebellar Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infant; Male; Medulloblastoma; Neoplasm Recurrence, Local; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1997 |
Pharmacological considerations of primary alkylators.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Thiotepa | 2002 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lenalidomide; Lymphoma, Non-Hodgkin; Methotrexate; Nivolumab; Pemetrexed; Procarbazine; Prospective Studies; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab; Temozolomide; Thiotepa; Vincristine | 2022 |
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
Topics: Adult; Bayes Theorem; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Network Meta-Analysis; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous | 2023 |
Trials
52 trial(s) available for busulfan and thiotepa
| Article | Year |
|---|---|
High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Busulfan; Central Nervous System; Child; Child, Preschool; Combined Modality Therapy; Digestive System; Drug Eruptions; Drug Tolerance; Female; Humans; Infant; Liver; Male; Thiotepa | 1992 |
Leukemia following chemotherapy for ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Leukemia; Melphalan; Multicenter Studies as Topic; Neoplasms, Multiple Primary; Ovarian Neoplasms; Registries; Risk Factors; Thiotepa | 1990 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Recurrence; Remission Induction; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1995 |
Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Combined Modality Therapy; Drug Tolerance; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Thiotepa; Transplantation, Autologous | 1994 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Diseases; Humans; Leukemia; Lymphoma; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Thiotepa; Transplantation, Homologous | 1994 |
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Hematologic Diseases; Humans; Male; Neoplasms; Preoperative Care; Risk Factors; Survival Analysis; Thiotepa | 1994 |
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Thiotepa; Transplantation, Autologous | 1993 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation | 1996 |
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neoplasms; Ovarian Neoplasms; Thiotepa; Transplantation, Autologous | 1996 |
A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Drug; Ependymoma; Female; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Reoperation; Thiotepa | 1996 |
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 1997 |
The role of thiotepa in autologous bone marrow transplantation for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 1998 |
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Blast Crisis; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Oncogene Proteins; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous | 1999 |
Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: immunologic consequences affecting clinical outcome.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Metastasis; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1999 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neuroblastoma; Prognosis; Rhabdomyosarcoma; Sarcoma, Ewing; Thiotepa | 1999 |
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Incidence; Liver Diseases; Male; Melphalan; Middle Aged; Multiple Organ Failure; Multivariate Analysis; Radiotherapy; Risk Factors; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1999 |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 1999 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Busulfan; Cause of Death; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sarcoma, Ewing; Survival Rate; Thiotepa; Treatment Outcome; Treatment Refusal | 2000 |
High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Staging; Survival Rate; Thiotepa; Time Factors | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Salvage Therapy; Thiotepa | 2001 |
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Survival Analysis; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2001 |
[Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Thiotepa; Transplantation Conditioning; Treatment Outcome | 2001 |
Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Thiotepa; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2003 |
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Child; Child, Preschool; Drug Interactions; Drug Monitoring; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Male; Melphalan; Neoplasms; Pharmacokinetics; Thiotepa; Transplantation, Autologous | 2003 |
High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Supratentorial Neoplasms; Thiotepa; Topotecan; Transplantation, Autologous; Treatment Outcome | 2005 |
High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Medulloblastoma; Neurotoxicity Syndromes; Remission Induction; Survival Rate; Thiotepa; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2005 |
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Thiotepa | 2007 |
Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Iron; Male; Melphalan; Neoplasms; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Thiotepa; Transferrin; Transplantation, Homologous; Treatment Outcome | 2007 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Eye Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Thiotepa | 2008 |
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Lomustine; Male; Middle Aged; Oligodendroglioma; Procarbazine; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Thiotepa; Vincristine | 2008 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2008 |
Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Central Nervous System Neoplasms; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2012 |
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2012 |
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Eye Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate; Thiotepa; Transplantation, Autologous | 2012 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gene Amplification; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Risk Factors; Thiotepa; Transplantation Conditioning | 2012 |
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Massachusetts; Middle Aged; Rituximab; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Procarbazine; Prognosis; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Vincristine; Young Adult | 2015 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine | 2016 |
Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa | 2016 |
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2019 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Autografts; Busulfan; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lymphoma; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning | 2019 |
Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Male; Melphalan; Neuroblastoma; Recurrence; Stem Cell Transplantation; Survival Rate; Thiotepa | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma.
Topics: Adolescent; Bone Neoplasms; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Osteosarcoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation | 2021 |
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine | 2022 |
Other Studies
131 other study(ies) available for busulfan and thiotepa
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of cancer chemotherapeutic agents on testicular DNA synthesis in the rat. Evaluation of a short-term test for studies of the genetic toxicity of chemicals and drugs in vivo.
Topics: Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; DNA; Dose-Response Relationship, Drug; Kinetics; Lomustine; Male; Mutation; Procarbazine; Rats; Testis; Thiotepa; Thymidine | 1979 |
[Combination chemotherapy of tumors (an experimental study)].
Topics: Animals; Antineoplastic Agents; Busulfan; Carcinoma, Ehrlich Tumor; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Synergism; Drug Therapy, Combination; Mice; Neoplasms, Experimental; Streptonigrin; Thiotepa; Time Factors; Vinblastine | 1975 |
Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Chimera; Cyclophosphamide; Female; Leukemia; Lymphocyte Depletion; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Whole-Body Irradiation | 1990 |
Anticlastogenic effect of beta-carotene in Chinese hamsters. Time and dose response studies with different mutagens.
Topics: Alkylating Agents; Animals; beta Carotene; Bone Marrow Cells; Busulfan; Carotenoids; Chromosome Aberrations; Cricetinae; Cricetulus; Cyclophosphamide; Female; Male; Methyl Methanesulfonate; Mutagenicity Tests; Mutagens; Thiotepa; Vitamin A | 1985 |
Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice.
Topics: Alkylating Agents; Allyl Compounds; Animals; Antineoplastic Agents; Biological Assay; Busulfan; Butanones; Carcinogens; Cinnamates; Dimethoate; Dioxoles; Female; Food Additives; Lung Neoplasms; Male; Mice; Mice, Inbred A; Mustard Compounds; Neoplasms, Experimental; Nitrogen Mustard Compounds; ortho-Aminobenzoates; Saccharin; Terpenes; Thiotepa; Uracil Mustard; Urethane | 1973 |
Thrombocythaemia. Familial occurrence and transition into blastic crisis.
Topics: Alkaline Phosphatase; Anemia, Aplastic; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Chromosome Aberrations; Female; Fibrinogen; Gastrointestinal Hemorrhage; Humans; Inclusion Bodies; Leukemia; Leukocytes; Male; Phosphorus Radioisotopes; Prothrombin Time; Thiotepa; Thrombocytosis | 1974 |
Antitumor activity of haloacetylphenothiazines against ascites sarcoma-180.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Iodoacetates; Mice; Neoplasm Transplantation; Phenothiazines; Pipobroman; Sarcoma 180; Thiotepa | 1972 |
[Side-effects of cytostatic and immunosuppressive therapy].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Chromosomes; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Spermatogenesis; Thiotepa; Triaziquone | 1973 |
[Experimental study of antitumor action of rubomycin in combination with some cytostatic compounds].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Drug Synergism; Lymphoma, Non-Hodgkin; Melphalan; Mercaptopurine; Mice; Neoplasms, Experimental; Nitrogen Mustard Compounds; Oligomycins; Thiotepa; Uracil Mustard | 1967 |
Enhanced growth of transplanted tumours after treatment with cytotoxic agents.
Topics: Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Ethers, Cyclic; Lymphoma; Mannomustine; Methotrexate; Mice; Neoplasms, Experimental; Plasmacytoma; Sarcoma 180; Stimulation, Chemical; Thiotepa; Triethylenemelamine | 1968 |
[Studies on the pharmacological characterization of a permanent in vitro growing strain of Ehrlich ascites tumor cells].
Topics: Animals; Antineoplastic Agents; Azaserine; Busulfan; Carcinoma, Ehrlich Tumor; Colchicine; Culture Techniques; Cyclophosphamide; Depression, Chemical; Diethylstilbestrol; Hydrazines; Immunosuppressive Agents; Mercaptopurine; Methotrexate; Thiotepa; Triaziquone; Urethane | 1968 |
Sensitivity of Nakahara-Fukuoka sarcoma to antitumor agents, especially to purine analogs.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Fluorouracil; Hydrocortisone; Mechlorethamine; Mercaptopurine; Methotrexate; Mice; Mitomycins; Purines; Sarcoma, Experimental; Thioguanine; Thiotepa; Uracil | 1969 |
Behavior of marrow stem cells in irradiated and non-irradiated mice after treatment with cytotoxic agents.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Busulfan; Clone Cells; Female; Male; Mice; Radiation Effects; Spleen; Thiotepa; Triethylenemelamine; Urethane | 1969 |
Nonhuman primates in evaluation of hematotoxicity.
Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug-Related Side Effects and Adverse Reactions; Folic Acid Antagonists; Haplorhini; Hematologic Diseases; Hematopoiesis; Infections; Leukocyte Count; Leukopenia; Mechlorethamine; Mercaptopurine; Models, Biological; Pyrimidines; Thiotepa; Triethylenemelamine; Vinblastine; Vincristine | 1969 |
[Effect of rubomycin in combination with some cytostatic preparations on formation of hemagglutinins in mice].
Topics: Animals; Antibiotics, Antineoplastic; Antibody Formation; Antineoplastic Agents; Azathioprine; Busulfan; Depression, Chemical; Drug Synergism; Erythrocytes; Immunosuppressive Agents; Melphalan; Mice; Olivomycins; Sheep; Skin Transplantation; Thiotepa; Time Factors | 1969 |
[Animal experimental studies on the immunosuppressive effect of cytostatic agents].
Topics: Animals; Antineoplastic Agents; Busulfan; Carcinogens; Cyclophosphamide; Fluorouracil; Hemagglutination Tests; Immunosuppressive Agents; Male; Mannomustine; Mercaptopurine; Methotrexate; Mitomycins; Rats; Spleen; Thiotepa; Triaziquone; Vinblastine | 1969 |
[Ototoxicity of nitrogen mustard-N-oxide (Nitromin)].
Topics: Animals; Audiometry; Busulfan; Cochlea; Cyclophosphamide; Guinea Pigs; Injections, Intravenous; Mechlorethamine; Microscopy, Phase-Contrast; Thiotepa; Time Factors | 1970 |
[2 cases of acquired latent focal toxoplasmosis of the brain in a cytostatic and corticosteroid treated neoplastic disease].
Topics: Autopsy; Brain; Brain Diseases; Busulfan; Female; Focal Infection; Glycine; Humans; Leukemia, Myeloid; Male; Middle Aged; Mustard Compounds; Ovarian Neoplasms; Phosphorus Isotopes; Prednisone; Thiotepa; Thymine; Toxoplasmosis | 1970 |
Immunosuppressive drugs in the treatment of immunologic iridocyclitis in the rabbit.
Topics: Animals; Aqueous Humor; Azathioprine; Busulfan; Drug Evaluation, Preclinical; Female; Hypersensitivity, Immediate; Immunosuppressive Agents; Male; Methotrexate; Orosomucoid; Rabbits; Sialic Acids; Thiotepa; Uveitis, Anterior | 1980 |
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation, Homologous; Whole-Body Irradiation | 1995 |
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Combined Modality Therapy; Drug Resistance; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Prognosis; Survival Rate; Thiotepa; Transplantation, Autologous | 1997 |
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 1997 |
Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Infant; Melphalan; Neoplasms; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 1998 |
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Ovarian Neoplasms; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1998 |
High dose chemotherapy for childhood ependymona.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Child; Ependymoma; Humans; Thiotepa | 1998 |
The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Lymphocyte Depletion; Male; Thiotepa; Transplantation, Homologous; Treatment Outcome | 1999 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Combined Modality Therapy; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Soft Tissue Neoplasms; Thiotepa; Transplantation, Autologous | 1999 |
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; Thiotepa; Transplantation, Homologous | 1999 |
Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Brain Stem Neoplasms; Busulfan; Cause of Death; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Glioma; Humans; Male; Pilot Projects; Prospective Studies; Stereotaxic Techniques; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2000 |
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Busulfan; Feasibility Studies; Female; Flushing; Hematopoietic Stem Cell Transplantation; Humans; Hypotension; Male; Melphalan; Middle Aged; Mucous Membrane; Neoplasms; Pilot Projects; Protective Agents; Sneezing; Thiotepa; Transplantation, Autologous; Vomiting | 2000 |
High-dose chemotherapy with autologous stem cell support in an adult with bone marrow relapse of medulloblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Busulfan; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Male; Medulloblastoma; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Thiotepa; Transplantation, Autologous | 2000 |
Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytomegalovirus Infections; Fatal Outcome; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Melphalan; Middle Aged; Thiotepa; Transplantation, Autologous | 2001 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Etoposide; Fatal Outcome; Fusarium; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mycoses; Thiotepa; Transplantation Conditioning | 2001 |
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Prognosis; Radiotherapy; Stem Cell Transplantation; Thiotepa; Transplantation, Homologous; Treatment Outcome | 2003 |
Effect of oxygen tension on the sensitivity of normal and tumor tissues to alkylating agents.
Topics: Alkylating Agents; Animals; Busulfan; Chlorambucil; Mechlorethamine; Oxygen; Sarcoma 180; Thiotepa; Triethylenemelamine | 1963 |
The chemotherapy of intrathoracic tumors.
Topics: Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Humans; Mechlorethamine; Methotrexate; Neoplasms; Prednisone; Progesterone; Testosterone; Thiotepa; Thoracic Neoplasms; Vinblastine | 1962 |
The effect of alkylating agents on the excretion of taurine in the urine of rats.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Busulfan; Radiation Effects; Rats; Taurine; Thiotepa | 1963 |
[Determination of alkylating agents in biological fluids. Method using the color reaction with 4-(4-nitrobenzyl)-pyridine in an alkaline medium].
Topics: Alkylating Agents; Antineoplastic Agents; Aziridines; Busulfan; Nitrogen Mustard Compounds; Pyridines; Thiotepa; Triethylenemelamine | 1963 |
[CLASSIFICATION OF LEUKEMIA BY SENSITIVITY OF CELLS TO DRUGS].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antimetabolites; Antineoplastic Agents; Busulfan; Classification; Colchicine; Humans; Leukemia; Nitrogen Mustard Compounds; Radiation; Radioisotopes; Thiotepa; Triethylenemelamine; Urethane | 1963 |
[EXPERIMENTAL STUDIES ON THE ANTITUMOR EFFECT OF OLIVOMYCIN IN ASSOCIATION WITH SOME SYNTHETIC CYTOSTATIC PREPARATIONS].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Busulfan; Cytostatic Agents; Lymphoma; Lymphoma, Non-Hodgkin; Mercaptopurine; Methylthiouracil; Mice; Neoplasms, Experimental; Nitrogen Mustard Compounds; Olivomycins; Pharmacology; Research; Thiotepa | 1963 |
[EXPERIMENTAL STUDIES ON THE ANTINEOPLASTIC EFFECT OF OLIVOMYCIN IN ASSOCIATION WITH SOME SYNTHETIC CYTOSTATIC DRUGS IN CROCKER'S SARCOMA].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Busulfan; Cytostatic Agents; Mercaptopurine; Mice; Olivomycins; Pharmacology; Research; Sarcoma; Sarcoma 180; Thiotepa; Uracil | 1963 |
[IMPROVEMENT AND EXACERBATION IN LEUKEMIA].
Topics: Aminocaproates; Aminocaproic Acid; Anemia; Antineoplastic Agents; Blood Transfusion; Busulfan; Central Nervous System; Fever; Hemorrhage; Humans; Leukemia; Mechlorethamine; Mercaptopurine; Nervous System; Physiology; Prednisolone; Thiotepa; Vitamin K 1 | 1963 |
DRUGS OF CURRENT USE FOR THE TREATMENT OF CANCER AND ALLIED DISEASES.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Busulfan; Colchicine; Dactinomycin; Diethylstilbestrol; Estrogens; Fluorouracil; Gonadal Steroid Hormones; Mercaptopurine; Methotrexate; Mitomycin; Mitomycins; Neoplasms; Podophyllum; Progestins; Quinones; Thiotepa; Triethylenemelamine; Urethane; Vinblastine | 1963 |
[PRESENT STATE OF ANTINEOPLASTIC CHEMOTHERAPY FROM THE PHARMACOLOGIC POINT OF VIEW].
Topics: Acridines; Antineoplastic Agents; Arsenicals; Azaguanine; Azaserine; Busulfan; Cell Division; Chloramines; Colchicine; Humans; Mercaptopurine; Pharmacology; Purines; Thiotepa; Triethylenemelamine | 1963 |
[MEDULLARY APLASIA DURING THE USE OF 4 ANTIMITOTICS: CARYOLYSIN, MYLERAN, THIOTEPA, ENDOXAN (APROPOS OF 32 CASES)].
Topics: Anemia; Anemia, Aplastic; Antimitotic Agents; Busulfan; Cyclophosphamide; Neoplasms; Nitrogen Mustard Compounds; Thiotepa; Toxicology | 1963 |
[CYTOSTATIC THERAPY].
Topics: Antineoplastic Agents; Breast Neoplasms; Busulfan; Chlorambucil; Colchicine; Cyclophosphamide; Female; Folic Acid Antagonists; Genetic Diseases, X-Linked; Humans; Intestinal Neoplasms; Leukemia; Leukemia, Hairy Cell; Lung Neoplasms; Lymphatic Diseases; Nitrogen Mustard Compounds; Ovarian Neoplasms; Purines; Pyrimidines; Severe Combined Immunodeficiency; Stomach Neoplasms; Thiotepa; Toxicology; Urethane; Urogenital Neoplasms; Vinblastine | 1964 |
EXPERIMENTAL STUDY OF OLIVOMYCIN, AN ANTITUMOUR ANTIBIOTIC.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Carcinoma, Ehrlich Tumor; Leukemia; Leukemia, Myeloid; Lymphoma; Lymphoma, Non-Hodgkin; Mercaptopurine; Mice; Neoplasms, Experimental; Nitrogen Mustard Compounds; Olivomycins; Pharmacology; Research; Sarcoma 180; Thiotepa; Toxicology | 1964 |
[INFLUENCE OF MYLERAN AND THIO-TEPA ON HETERO-HEMAGGLUTININ PRODUCTION IN VARIOUS LABORATORY ANIMALS (RABBIT, RAT, GUINEA PIG)].
Topics: Animals; Animals, Laboratory; Antibody Formation; Busulfan; Chlorambucil; Guinea Pigs; Hemagglutinins; Immunization; Pharmacology; Rabbits; Rats; Research; Thiotepa; Vaccination | 1964 |
THE TREATMENT OF INCURABLE MALIGNANT DISEASE.
Topics: Adrenalectomy; Androgens; Breast Neoplasms; Busulfan; Chlorambucil; Estrogens; Heroin; Hormones; Humans; Hypophysectomy; Male; Morphine; Neoplasm Metastasis; Neoplasms; Pain; Palliative Care; Prostatic Neoplasms; Surgical Procedures, Operative; Thiotepa; Toxicology | 1964 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Eye Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell; Middle Aged; Prognosis; Recurrence; Thiotepa | 2004 |
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Humans; Melphalan; Middle Aged; Multiple Myeloma; Retrospective Studies; Thiotepa; Treatment Outcome | 2004 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Dose-Response Relationship, Drug; Humans; Infant; Lung Diseases, Fungal; Medulloblastoma; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Radiotherapy, Conformal; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thiotepa; Treatment Outcome | 2007 |
The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease Models, Animal; Drug Synergism; Hematopoietic Stem Cell Transplantation; Leukemia, B-Cell; Mice; Mice, Inbred BALB C; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2007 |
Symptom burden after autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Remission Induction; Severity of Illness Index; Survival Rate; Thiotepa; Topotecan; Transplantation, Autologous; Tumor Burden | 2008 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Clonazepam; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Retrospective Studies; Risk Factors; Sarcoma; Seizures; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2008 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
Topics: Adult; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2010 |
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Humans; Methylprednisolone Hemisuccinate; Neuroectodermal Tumors, Primitive; Neuroprotective Agents; Radiotherapy; Spinal Neoplasms; Temozolomide; Thiotepa; Thoracic Vertebrae; Vincristine; Young Adult | 2011 |
BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Risk Factors; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2012 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Salvage Therapy; Thiotepa; Young Adult | 2011 |
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
[Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Thiotepa; Transplantation, Homologous; Vascular Neoplasms | 2011 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carmustine; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Salvage Therapy; Stem Cell Transplantation; Thiotepa; Vincristine; Young Adult | 2013 |
Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival.
Topics: Adolescent; Brain; Brain Neoplasms; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Infant; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Myeloablative Agonists; Prognosis; Radiotherapy; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous | 2012 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Successful treatment of a recurrent choroid plexus carcinoma with surgery followed by high-dose chemotherapy and stem cell rescue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carcinoma; Choroid Plexus Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Li-Fraumeni Syndrome; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Remission Induction; Thiotepa; Transplantation, Autologous | 2013 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Staging; Prognosis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infant; Infratentorial Neoplasms; Male; Medulloblastoma; Neuropsychological Tests; Prognosis; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous | 2014 |
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2015 |
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fibrinogen; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning; Young Adult | 2014 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine | 2015 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult | 2015 |
Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2016 |
Permanent chemotherapy-induced nonscarring alopecia and premature ovarian failure.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Primary Ovarian Insufficiency; Thiotepa; Vidarabine | 2015 |
High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Preoperative Period; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Cohort Studies; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Prospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Treatment Outcome | 2015 |
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Methotrexate; Middle Aged; Prognosis; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Vincristine | 2016 |
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2017 |
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2017 |
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
Topics: Adult; Bilirubin; Busulfan; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Gilbert Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Washington; Whole-Body Irradiation | 2016 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Remission Induction; Retrospective Studies; Rituximab; Stem Cell Transplantation; Temozolomide; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2017 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission.
Topics: Busulfan; Child; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Thiotepa; Transplantation, Autologous | 2017 |
High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2017 |
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.
Topics: Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Female; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous | 2018 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Thiotepa; Transplantation, Autologous; Treatment Outcome; Young Adult | 2019 |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult | 2018 |
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma; Male; Middle Aged; Prospective Studies; Registries; Stem Cell Transplantation; Survival Rate; Thiotepa | 2019 |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Thiotepa | 2020 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2021 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
Topics: Adult; Aged; Busulfan; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Thiotepa; Thrombocytopenia; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2021 |
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Primary Myelofibrosis; Splenectomy; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning | 2021 |
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine | 2021 |
Second haploidentical stem cell transplantation for primary graft failure.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Thiotepa; Transplantation Conditioning | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma?
Topics: Busulfan; Central Nervous System; Humans; Lymphoma; Thiotepa; Transplantation Conditioning | 2021 |
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Neoplasm Recurrence, Local; Thiotepa; Transplantation, Autologous | 2021 |
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Melphalan; Thiotepa; Transplantation Conditioning; Vidarabine | 2022 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2022 |
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Methotrexate; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Rituximab; Thiotepa; Transplantation, Autologous; Treatment Outcome; Young Adult | 2022 |
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult | 2022 |
Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Intercellular Signaling Peptides and Proteins; Retrospective Studies; Thalassemia; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
[Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Doxorubicin; Humans; Lymphadenopathy; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Rituximab; Thiotepa; Transplantation, Autologous; Vincristine | 2022 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; T-Lymphocytes; Thiotepa; Transplantation Conditioning | 2023 |
Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Thiotepa; Transplantation, Autologous | 2023 |
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.
Topics: Anemia, Sickle Cell; Busulfan; Child; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Thiotepa | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |